Pharmaceutical Executive December 12, 2024
Mike Hollan

The industry is facing an uncertain regulatory landscape in the coming year.

The recent election of Donald Trump as president of the United States is sure to have a significant impact on many industries, including the pharmaceutical and life sciences industries. Whether its actions that will have a direct impact, such as naming Robert F. Kennedy Jr to be head of the Department of Health and Human Services, or indirect impacts, such as his plans to place tariffs on certain goods, the industry is preparing for an uncertain regulatory landscape. Arthur Wong, health care managing director at S&P Global Rankings, spoke with Pharmaceutical Executive about the potential impacts of the election.

Pharmaceutical Executive: How will the expiration of ACA subsidies...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Interview / Q&A, Pharma, Pharma / Biotech, Trends
Which Biopharma Startups Made the Cut for INVEST Pitch Perfect?
PBMs push private-label biosimilars in 2025 formularies
CAR T-Cell Pioneer Plots Technology’s Next Steps
Eli Lilly Adds Alzheimer’s Care to Digital Health Platform Services
GLP-1 drug use for weight loss has soared, costing billions

Share This Article